 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
| «12...678910111213141516...1718» |
- ||| Tecvayli (teclistamab) / Genmab, J&J
“Teclistamab will be therefore be very important as a treatment option for refractory disease.” @VincentRK Adding: “I am however concerned about prolonged weekly therapy & risk of serious infections & other complications it can bring along.” https://t.co/d8UeczKYT7 (Twitter) - Oct 26, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Exciting day in #multiplemyeloma! The 1st bispecific antibody approved for MM: teclistamab is now available for RRMM after ≥4 prior lines of therapy including a PI, IMID, and anti-CD38 mAb based on the single-arm MajesTEC-1 study#MMSM @szusmani https://t.co/xoKpeWkmKO (Twitter) - Oct 26, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Today’s FDA approval of teclistamab-cqyv to treat multiple myeloma is a critical step forward for improving prognosis when other therapies haven't worked. Dr. Usmani (@szusmani), who played a key role in clinical testing, says the results were remarkable. https://t.co/kU7mNdBDz7 (Twitter) - Oct 26, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Breaking: The FDA just granted accelerated approval of teclistamab for people with relapsed/refractory #multiplemyeloma. Congrats to DoM's @szusmani and the team who led the phase 1/2 trial that resulted in the drug's approval. #mmsm https://t.co/pCxIGZBLXV (Twitter) - Oct 26, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
$JNJ TECVAYLI approved $GMAB cc @bradloncar 😉 (Twitter) - Oct 25, 2022
- ||| Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J
In myeloma, J&J has developed many really important treatments, Daratumumab, cilta-cel, and now teclistamab with more to come. Dara alone has already had a major impact on the field. (Twitter) - Oct 25, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/rzaMKvknPF ▶️Teclistamab（BCMA×CD3-BiTE） ▶️MajesTEC-1（NEJM 2022; 387: 495-505） phase 1（NCT03145181）iv vs sc DLT, AEs phase 2（NCT04557098）sc at an RP2D. ORR（IMWG） よいです (Twitter) - Oct 25, 2022
P1, P2
- ||| Tecvayli (teclistamab) / Genmab, J&J
Ooft that is a game-changing drug with a hefty price (teclistamab for myeloma; continuous admin) @bnrome @wbfeldman reckon it's in anticipation of the IRA changes? cc @VincentRK @HadidiSamer @JanakiramMurali @RahulBanerjeeMD @HiraSMian @amarkelkar @ShoMidha (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: What does the teclistamab approval mean for patient with MM in 🇮🇳 NOTHING, ABSOLUTELY NOTHING 😭 My question to 🇮🇳 oncologists, how do you treat a triple class refractory patient ?? #MedTwitter @DrNikitaMehra @Prasshmehta @chepsyphilip @NicoGagelmann @nesrinebensaye1 (Twitter) - Oct 25, 2022
- || Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Tecvayli (teclistamab) / Genmab, J&J
While the trial got it approved, RWE will guide how to give #TECLISTAMAB for #RRMM -Can we give 3 mg/kg every 2 or 4 wks? #MAJESTEC-3 -Can we give Dex ppx to avoid CRS and give it OutPt? -Evusheld for all but also IVIG? @Abdallah81MD @AtrashShebli already getting ideas #USMIRC (Twitter) - Oct 25, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Teclistimab is the first BiTE FDA approved for RRMM! more are available in the near future with different targets! All #myeloma patients must receive at least one BCMA directed therapy in triple Class RRMM #mmsm #medtwitter #USMIRC #MedEd (Twitter) - Oct 25, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Teclistamab granted accelerated approval today by the FDA. This BCMAxCD3 bispecific T-cell engager is likely the first of many BiTEs to come against #myeloma. A good day! https://t.co/Q3BzeYFY4w (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: What is your plan for patients starting on therapy with teclistamab now that it has FDA approval? #mmsm #bcma #bmtsm (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: From the perspective of limited CAR-T spots, would try commercial teclistamab, if they progress on that then could try clinical trial but would expect around a 1 yr. Some data for reduced efficacy of BCMA CAR-T after BCMA-based treatment. Other option is GPRC5D CAR-T trial. (Twitter) - Oct 25, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Cytogenetics? Would favor teclistamab over CAR-T in high risk cytogenetics #myeloma. (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: Oncology Twitter Now that teclistamab is approved… You have a 70 year old patient that has progressed after 4 treatments (including Len/pom, CD38 MAB, auto, PIs). Their performance ECOG 1. They are not progressing rapidly. You recommend off trial (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Well done #myeloma RT @MSK_DeptOfMed: Breaking: The FDA just granted accelerated approval of teclistamab for people with relapsed/refractory… https://t.co/mvR6Ru80lG (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: WATCH: Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma @AlGarfall @PennMedicine @US_FDA #mmsm https://t.co/6x8ZOgubIp (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Thrilled to have another option for patients!! U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with #RRMM https://t.co/2DeBkFxUnI (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Well done #myeloma RT @DrOlaLandgren: BREAKING NEWS: The FDA has approved teclistamab-cqyv (Tecvayli) for patients with relapsed/refractory myeloma with… https://t.co/8Z9mW6NEVY (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/KOuh6nZBVK #mmsm (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/KOuh6nZBVK (Twitter) - Oct 25, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
Teclistamab once / week untill progression or CAR-T? (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA Grants Accelerated Approval to Teclistamab for Relapsed/Refractory Multiple Myeloma https://t.co/3lwq6zBWN0 via @targetedonc (Twitter) - Oct 25, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
Teclistamab approved!🙌https://t.co/Qj0kr2Gysa (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma https://t.co/5lNiDHjxCb via @onclive (Twitter) - Oct 25, 2022
- |||| Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Tecvayli (teclistamab) / Genmab, J&J, Blenrep (belantamab mafodotin) / GSK
Other BCMA directed immunotherapies in myeloma such as CART products (ide cel and cilta cel) and ADCs (belantamab) have many issues that limit their use. So I welcome the approval of Teclistamab. It fills an unmet need. 5/ (Twitter) - Oct 25, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Teclistamab is the first of many bispecifics in myeloma, most of which target BCMA. Im also happy that there are bispecifics being developed against other myeloma cell antigens as well. As a class immunotherapy using bispecifics holds a lot of promise. 4/ (Twitter) - Oct 25, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Teclistamab is a first in class novel bispecific antibody targeting BCMA antigen on myeloma cells. Data supporting its approval was published earlier in @NEJM by @szusmani @TomBmt133 @mvmateos @SurbhiSidanaMD et al. 2/ (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: Teclistamab granted accelerated approval for relapsed refractory myeloma in the US, for patients who have received at least 4 prior lines of therapy. This is an important new option for myeloma. https://t.co/dWrHRhN6ch 1/ (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval teclistamab-cqyv for patients with relapsed/refractory multiple myeloma. #mmsm | @US_FDA @FDAOncology @jmikhaelmd https://t.co/ATzJ1ndD5d (Twitter) - Oct 25, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event, P2 data: Wonderful news for our MM patients. FDA approval for teclistamab. Grateful to our research study team @StanfordBMT_CT for their hard work and glad to be a part of the phase 2 trial that led to the FDA approval. Indication ~ to CAR-T, after 4 prior lines of therapy (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Great news!! Teclistamab FDA approved #mmsm (Twitter) - Oct 25, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: BREAKING NEWS: The FDA has approved teclistamab-cqyv (Tecvayli) for patients with relapsed/refractory myeloma with at least 4 prior lines of therapy incl proteasome inhibitor, iMID & CD38-targeted antibody #mmsm @IMFmyeloma @theMMRF https://t.co/3haeDpJIYy (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, P1 data: Wonderful news for myeloma patients. So proud of and grateful to my colleagues @PennCancer and our patients who participated in the phase 1 & 2 trials of teclistamab. (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma!!!! https://t.co/8sOkgEKTw3 via @onclive (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma | FDA #mmsm @MSKCancerCenter @MSK_DeptOfMed https://t.co/Gi8y3EQ2fU (Twitter) - Oct 25, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Will likely need some time to figure those details: "Because of the risks of CRS and neurologic toxicity, including ICANS, teclistamab-cqyv is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the Tecvayli REMS." (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: #mmsm Great to see teclistamab approved to offer to patients in need 👇 ➡️4 or more previous ttt: PI, IMED and anti-CD38 ➡️Under REMS ➡️Dose:0.06 mg/kg via subcutaneous injection on Day 1, 0.3 mg/kg on Day 4, and 1.5 mg/kg on Day 7, followed by 1.5 mg/kg once weekly (Twitter) - Oct 25, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Teclistamab approved in 5L+ triple-class exposed RRMM #MMSM @VincentRK @szusmani @SagarLonialMD https://t.co/gvHp53ZkP9 (Twitter) - Oct 25, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical, FDA event: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://t.co/CJQa3D3WhG so can I send pts on Tecistimab EAP back to their local oncologists?? #mmsm #myeloma #MedTwitter #USMIRC (Twitter) - Oct 25, 2022
- || Tecvayli (teclistamab) / Genmab, J&J, Rybrevant (amivantamab-vmjw) / Genmab, J&J
Tecvayli expected to be approved before Roche I think for TCEs (otherwise Rybrevant already approved). (Twitter) - Oct 19, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: But of course all the more incentive for us to figure out outpatient CAR-T workflows since hospital beds are so tight… especially with teclistamab incoming! (Twitter) - Oct 19, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
CAR T-Cell Therapy: Joseph Mikhael, MD, spoke about the mechanism of action of bispecific antibody teclistamab relative to other agents in the space such monoclonal antibodies and CAR T-cell therapies in multiple myeloma. #mmsm | @jmikhaelmd @TGen https://t.co/AssaTDGBL7 (Twitter) - Oct 13, 2022
- | Tecvayli (teclistamab) / Genmab, J&J
New P2 trial, Combination therapy: IFM 2021-01: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 7, 2022
P2, N=82, Not yet recruiting, Sponsor: University Hospital, Lille
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Enrollment change, Combination therapy, Checkpoint inhibition: TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 7, 2022
P1b, N=76, Recruiting, Sponsor: Janssen Research & Development, LLC
N=152 --> 76
- |||||||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
New P3 trial, Monotherapy: MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 7, 2022
P3, N=590, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| BCMA CAR-T:Cilta-Cel/Ide-Cel/BCMA BiTE:Teclistamab; GPRC5D BiTE:Talquetamab and now GPRC5D CAR T in relapse myeloma. Many effective treatment options in RRMM #mmsm #myeloma https://t.co/nJogZZS5cF #MedTwitter #USMIRC (Twitter) - Sep 28, 2022
- |||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment open, Combination therapy: MajesTEC-4: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (clinicaltrials.gov) - Sep 28, 2022
P3, N=1000, Recruiting, Sponsor: European Myeloma Network
N=152 --> 76 Not yet recruiting --> Recruiting
- |||| Tecvayli (teclistamab) / Genmab, J&J
PDUFA date: What is teclistimab's PDUFA date? Why have I heard nothing Is FDAOnc taking the infections seriously? Who knows what is going on? If anyone is curious what I am talking about see: https://t.co/UF0r0svvFF (Twitter) - Sep 27, 2022